Susan E. Bennett, EdD, will examine the effectiveness of Dalfampridine, an FDA-approved medication to improve walking in patients with multiple sclerosis, when combined with a physical therapy program.
Principal Investigator: Susan
E. Bennett, EdD
Funding Agency: Acorda Therapeutics, Inc.
Abstract: The project will examine the effectiveness of Dalfampridine when administered in conjunction with a 12-week physical therapy program for non-ambulatory individuals living with multiple sclerosis.